[{"orgOrder":0,"company":"Alentis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"GlucoCorticoid","moa":"||CLDN1","graph1":"Immunology","graph2":"Phase II","graph3":"Alentis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alentis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alentis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alentis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Glucocorticoid","moa":"||CLDN1","graph1":"Immunology","graph2":"Phase II","graph3":"Alentis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alentis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alentis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SHL Medical AG","sponsor":"MoonLake Immunotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Collaboration","leadProduct":"Adalimumab","moa":"||IL-17A\/IL-17F receptor","graph1":"Immunology","graph2":"Phase II","graph3":"SHL Medical AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"SHL Medical AG \/ MoonLake Immunotherapeutics","highestDevelopmentStatusID":"8","companyTruncated":"SHL Medical AG \/ MoonLake Immunotherapeutics"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"I-Mab Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Protein","year":"2022","type":"Collaboration","leadProduct":"Olamkicept","moa":"IL-6 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ferring Pharmaceuticals \/ I-Mab Biopharma","highestDevelopmentStatusID":"8","companyTruncated":"Ferring Pharmaceuticals \/ I-Mab Biopharma"},{"orgOrder":0,"company":"BaseLaunch","sponsor":"Bridge Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Peptide","year":"2020","type":"Partnership","leadProduct":"BBT-401","moa":"Pellino-1","graph1":"Immunology","graph2":"Phase II","graph3":"BaseLaunch","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BaseLaunch \/ Bridge Biotherapeutics","highestDevelopmentStatusID":"8","companyTruncated":"BaseLaunch \/ Bridge Biotherapeutics"},{"orgOrder":0,"company":"VectivBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Apraglutide","moa":"GLP-2 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"VectivBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VectivBio \/ Inapplicable"},{"orgOrder":0,"company":"VectivBio","sponsor":"Asahi Kasei Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Apraglutide","moa":"GLP-2 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"VectivBio \/ Asahi Kasei Pharma","highestDevelopmentStatusID":"8","companyTruncated":"VectivBio \/ Asahi Kasei Pharma"},{"orgOrder":0,"company":"VectivBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Apraglutide","moa":"GLP-2 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"VectivBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VectivBio \/ Inapplicable"},{"orgOrder":0,"company":"VectivBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Apraglutide","moa":"GLP-2 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"VectivBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VectivBio \/ Inapplicable"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : ALE.F02 (lixudebart) is a claudin 1 inhibitor antibody, which is currently being evaluated for antineutrophil cytoplasmic antibody-associated vasculitis with rapidly progressive glomerulonephritis.

                          Product Name : ALE.F02

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          January 09, 2025

                          Lead Product(s) : Lixudebart,GlucoCorticoid,Rituximab

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : M1095 (sonelokimab) is an investigational 40kDa humanized nanobody. It is currently being assessed in lead indications of pateints suffering from psoriatic arthritis.

                          Product Name : M1095

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          October 06, 2024

                          Lead Product(s) : Sonelokimab

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : M1095 (sonelokimab) is a humanized nanobody consisting of three VHH domains covalently linked by flexible glycine-serine spacers. It selectively binds with IL-17A and IL-17F and inhibit IL-17A/A, IL-17A/F, and IL-17F/F dimer, which investigated for psori...

                          Product Name : M1095

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          July 25, 2023

                          Lead Product(s) : Sonelokimab

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : MoonLake intends to use the proceeds to fund the ongoing advancement of M1095, a novel investigational Nanobody® for the treatment of inflammatory disease. Sonelokimab inhibits IL-17A and IL-17F by inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F dimers ...

                          Product Name : M1095

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          June 26, 2023

                          Lead Product(s) : Sonelokimab

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : SVB Securities

                          Deal Size : $250.0 million

                          Deal Type : Public Offering

                          blank

                          05

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : ALE.F02 (Lixudebart Rituximab GlucoCorticoid) is a claudin 1 inhibitor antibody drug candidate, which is currently being evaluated for the treatment of antineutrophil cytoplasmic antibody-associated vasculitis with rapidly progressive glomerulonephritis.

                          Product Name : ALE.F02

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          May 12, 2023

                          Lead Product(s) : Lixudebart,Glucocorticoid,Rituximab

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : Apraglutide is a novel long-acting glucagon-like peptide-2 analog designed for to increase fluid and nutrient absorption by the remnant intestine of patients who have short bowel syndrome with intestinal insufficiency or intestinal failure.

                          Product Name : FE203799

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          March 13, 2023

                          Lead Product(s) : Apraglutide

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : Asahi Kasei Pharma

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : The collaboration aims to develop an autoinjector for clinical and potential subsequent commercial supply of MoonLake’s Nanobody® M1095 (sonelokimab) by using SHL Medical's market-proven Molly® modular platform technology.

                          Product Name : M1095

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          March 05, 2023

                          Lead Product(s) : Sonelokimab,Adalimumab

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : MoonLake Immunotherapeutics

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          08

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : MoonLake plans to execute on its development program to unlock the potential of M1095 (Sonelokimab), the novel investigational Nanobody® for the treatment of inflammation, to revolutionize outcomes for patients with inflammatory diseases.

                          Product Name : M1095

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          December 14, 2022

                          Lead Product(s) : Sonelokimab

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : This new collaboration enables Ferring to invest in the development of olamkicept globally and provides an option for I-Mab to collaborate with Ferring in the future development of olamkicept at a pre-defined development milestone.

                          Product Name : TJ-301

                          Product Type : Protein

                          Upfront Cash : Undisclosed

                          September 06, 2022

                          Lead Product(s) : Olamkicept

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : I-Mab Biopharma

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          10

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : FE203799 (apraglutide) is a next-generation, synthetic GLP-2 analog rationally designed with the potential to offer an improved safety and efficacy profile relative to other agents in its class and less frequent dosing.

                          Product Name : FE203799

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          February 06, 2022

                          Lead Product(s) : Apraglutide

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank